November 22, 2016 - By Hazel Jackson · 0 Comments
Nov 22 is a negative day so far for Direxion Daily S&P Biotech Bull 3X ETF (NYSEARCA:LABU) as the ETF is active during the day after losing 8.34% to hit $41.66 per share. The exchange traded fund has 235.42M net assets and 9.18% volatility this month.
Over the course of the day 438,689 shares traded hands, as compared to an average volume of 3.19M over the last 30 days for Direxion Daily S&P Biotech Bull 3X ETF (NYSEARCA:LABU).
The ETF is -55.04% of its 52-Week High and 138.79% of its low, and is currently having ATR of 3.8. This year’s performance is -46.24% while this quarter’s performance is 2.72%.
The ETF’s YTD performance is -65.7%, the 1 year is -62.4% and the 3 year is NaN%.
The ETF’s average P/E ratio is 21.11, the price to book is 3.23, the price to sales is 8.39 and the price to cashflow is 11.96. It was started on 5/28/2015. The fund’s top holdings are: S&P Biotechnology Select Industry USD for 90.25% of assets, S&P Biotechnology Select for 58.05%, Goldman Finl Sq Trsry Ins for 9.45%, SPDRÂ® S&P Biotech ETF for 3.60%, Fidelity Institutional Go for 0.00%. The ETF sector weights are: Healthcare 100.00%. The ETF currently as yield.
More notable recent Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) news were published by: Marketwatch.com which released: “Direxion Daily S&P Biotech Bull 3X Shares” on March 08, 2014, also Quotes.Wsj.com with their article: “DOW JONES, A NEWS CORP COMPANY” published on May 29, 2015, Etftrends.com published: “Triple-Leveraged Biotech ETFs Could be Coming Soon” on March 20, 2015. More interesting news about Direxion Daily S&P Biotech Bull 3X Shares (NYSEARCA:LABU) were released by: Investorplace.com and their article: “Be Careful Before Loving Leveraged Biotech ETFs” published on October 06, 2015 as well as Etftrends.com‘s news article titled: “Direxion to Reverse Split 8 ETFs, Forward Split Two Others” with publication date: February 24, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Hazel Jackson